For the year ending 2025-12-31, SGMO had -$22,470K decrease in cash & cash equivalents over the period. -$97,310K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -122,932 |
| Impairment of long-lived assets | 13,235 |
| Depreciation and amortization | 3,961 |
| Amortization of operating lease right-of-use assets | 3,641 |
| Stock-based compensation | 9,079 |
| Gain on sale of assets classified as held for sale | 0 |
| Other | -32 |
| Accounts receivable | -155 |
| Refundable research income tax credits | 0 |
| Prepaid expenses and other assets | -830 |
| Accounts payable and other accrued liabilities | 2,794 |
| Accrued compensation and employee benefits | 3,053 |
| Deferred revenues | -6,657 |
| Lease liabilities | -4,047 |
| Other non-current liabilities | -352 |
| Net cash used in operating activities | -97,208 |
| Maturities of marketable securities | 0 |
| Proceeds from sale of marketable securities | 0 |
| Proceeds from sale of assets classified as held for sale | 0 |
| Purchases of property and equipment | 102 |
| Net cash (used in) provided by investing activities | -102 |
| Proceeds from at-the-market offering, net of offering expenses | 52,185 |
| Proceeds from issuance of common stock, net of offering expenses | 21,483 |
| Taxes paid related to net share settlement of equity awards | 3,263 |
| Proceeds from issuance of common stock under employee stock purchase plan | 344 |
| Net cash provided by financing activities | 70,749 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 4,091 |
| Net decrease in cash, cash equivalents and restricted cash | -22,470 |
| Cash, cash equivalents and restricted cash, beginning of period | 43,418 |
| Cash, cash equivalents and restricted cash, end of period | 20,948 |
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)